Vaccination against Marek's disease and infectious bursal disease. II. Titration and in vivo efficacy of the coinfection-derived bivalent live vaccine for turkey herpesvirus and infectious bursal disease virus.
The bivalent HVT/IBDV live vaccine, developed by cocultivation of the turkey herpesvirus (HVT) and infectious bursal disease virus (IBDV) vaccine in cell cultures, was quantitated. The titer of each constituent virus could be successfully determined in vitro by pretreatment of the vaccine with anti-IBDV serum or chloroform (CHCl3). Studies in vivo further demonstrated that the anti-IBDV serum-treated HVT/IBDV vaccine lost its immunogenicity by failing to induce IBDV-neutralizing antibody or to protect vaccinates from bursal atrophy after challenge exposure to infectious bursal disease. The CHCl3 treatment significantly reduced the efficacy of the vaccine to protect vaccinates against Marek's disease challenge.